alcohol consumption because of a theoretical hepatotoxic interaction between alcohol and MTX. However, data are limited supporting this advice. The aim of this study was to quantify, using routinely collected clinical data, the association between alcohol consumption and abnormal serum liver function tests (LFTs) in such patients. Methods: Patients with RA in the Clinical Practice Research Database (CPRD) starting MTX between 1987 and 2011 were studied. Patients were included if they had alcohol consumption details recorded in the CPRD and six or more LFTs per year, indicating adequate monitoring. Patients were grouped by reported weekly alcohol consumption. Crude rates of abnormal LFTs (defined as aspartate transaminase/ alanine transaminase !3 times the upper limit of normal) per 1000 person-years of follow-up were calculated. Cox proportional hazards models described the association between alcohol consumed and the development of abnormal LFTs while taking MTX univariately, then adjusting for age and gender. Patients were censored at the time of first abnormal LFT, death or the end of follow-up (31 December 2011). Results: A total of 8801 patients were included in the study [6285 (71%) female, mean age 58 years (S.D. 14)]. There were 241 abnormal LFTs in 38 000 person-years of follow-up. There was no difference in the rates of abnormal LFTs between drinkers and non-drinkers [adjusted hazard ratio (HR) 1.12 (95% CI 0.82, 1.51)]. Crude rates of abnormal LFTs appeared to increase with increasing levels of alcohol consumption ( 
